cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit cagrisema semaglutide cagrilintide phase 3

If you have type 2 diabetes and have been diagnosed with heart disease or chronic kidney disease, this update is worth raising with your doctor or endocrinologist at your next appointment

In the study, those who lost more muscle didnt benefit as much from the drugs effects on blood sugar

Diabetes Ther 11(3):573584

If your fatigue becomes debilitating or is accompanied by severe symptoms like confusion or intense abdominal pain, you should consult a healthcare professional to discuss dose adjustments or potential nutritional deficiencies

ACHIEVE-1 (fase 3, diabetes type 2 eerste succesvolle fase 3 voor een niet-peptide GLP-1) 559 volwassenen met vroege diabetes type 2, 40 weken behandeling